The emerging new class of in vivo CAR T therapeutics is seen by regulators as gene therapies with risks of off-target effects to patients. Manufacturers need to rise to the challenge. The post In vivo CAR T Industry Leaps Forward with Challenges Ahead appeared first on GEN – Genetic Engineering and Biotechnology News.
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.